Global Alzheimer Drugs Market (2022 Edition) – Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)

Global Alzheimer Drugs Market (2022 Edition) – Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)

Executive Summary

According to Azoth Analytics research report, the Global Alzheimer's Drugs Market was valued at USD 6537.0 Million in the year 2021.

Diabetes, obesity, heart diseases and high blood pressure (BP), in confluence with sedentary lifestyles, unhealthy dietary patterns and smoking, are some of the factors known to increase the chances of developing Alzheimer's's disease. An increase in the prevalence of these ailments and lifestyle choices among the masses, coupled with the rising geriatric population, represents one of the key factors driving the market growth. Furthermore, the leading pharmaceutical companies are focusing on the development of drugs that prevent the disease and provide long-lasting improvements in cognitive functions.

In addition, the market growth is further supported by the expansion of telehealth services and the growing traction of online pharmacies. Telehealth can be defined as the remote delivery of clinical as well as non-clinical services through tele- and digital communication technologies. These platforms have enabled disease diagnosis and drug delivery in remote regions. Apart from this, various Alzheimer's's drugs are presently under late-stage clinical trials, including Aducanumab and Solanezumab. The development of these drugs is anticipated to propel market growth in the coming years.

Moreover, the increasing prevalence of Alzheimer's disease is fueling the demand for Alzheimer's drugs which in turn is driving the global Alzheimer's drugs market. Also, rising R&D activities by pharmaceutical companies and research institutes for Alzheimer's’ effective therapy is expected to boost the global Alzheimer's drugs market.

Scope of the Report

  • The report presents the analysis of the Alzheimer's's Drugs market for the historical period of 2017-2021 and the forecast period of 2022-2027.
  • The report analyses the Alzheimer's Drugs Market by Value (USD Million)
  • The report analyses the Alzheimer's Drugs Market by Drug Class (Cholinergic, Memantine, Combined drug, others).
  • The report analyses the Alzheimer's Drugs Market by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • The Global Alzheimer's Drugs Market has been analysed By Region (North America, Europe, Asia Pacific and LAMEA).
  • The Global Alzheimer's Drugs Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, India, Australia).
  • The attractiveness of the market has been presented by region, by Drug Class and By Distribution Channel.
  • Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development.
  • The companies analysed in the report include AbbVie Inc., F. Hoffman-La Roche, Ltd., Novartis AG, Biogen, Pfizer Inc., Eli Lilli and Company, Takeda Pharmaceutical Company Limited, Novo Nordisk, Daiichi Sankyo Company Ltd., Eisai Co. Ltd, NervGen Pharma.
Key Target Audience
  • Alzheimer's Drug Manufacturers
  • Pharmaceutical and Healthcare Companies
  • Consulting and Advisory Firms
  • Government and Policy Makers
  • Regulatory Authorities


1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Alzheimer's Drugs Market: Product Outlook
4. Global Alzheimer's Drugs Market: Sizing and Forecast
4.1 Global Alzheimer's Drugs Market Size, By Value, Year 2017-2027
Table 1: Global Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 2: Global Number of People With Dementia, in Million, in Low, Middle and High In come Countries, 2015-2020
Table 3: Worldís leading causes of death (in millions), 2019
Table 4: World Population 65 Years & Above (% of Total), 2015-2019
Table 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 6: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Table 7: Global Alzheimer's - Number of Drugs by Phase, In Percentage, 2020
4.2 Impact of COVID-19 on Global Alzheimer's Drugs Market
5. Global Alzheimer's Drugs Market Segmentation - By Drug Class, By Distribution Channel
5.1 Competitive Scenario of Global Alzheimer's Drugs Market: By Drug Class
Table 8: Global Alzheimer's Drugs Market- By Drug Class Market Share, 2021 & 2027
5.1.1 Cholinergic - Market Size and Forecast (2017-2027)
Table 9: Global Alzheimer's Drugs Market- By Cholinergic, By Value (USD Million), 2017-2027
5.1.2 Memantine - Market Size and Forecast (2017-2027)
Table 10: Global Alzheimer's Drugs Market- By Memantine, By Value (USD Million), 2017-2027
5.1.3 Combined drug - Market Size and Forecast (2017-2027)
Table 11: Global Alzheimer's Drugs Market- By Combined drug, By Value (USD Million), 2017-2027
5.1.4 Others - Market Size and Forecast (2017-2027)
Table 12: Global Alzheimer's Drugs Market- By Others, By Value (USD Million), 2017-2027
5.3 Competitive Scenario of Global Alzheimer's Drugs Market: By Distribution Channel
Table 13: Global Alzheimer's Drugs Market- By Distribution Channel Market Share, 2021 & 2027
5.3.1 Hospitals Pharmacy - Market Size and Forecast (2017-2027)
Table 14: Global Alzheimer's Drugs Market- By Hospital Pharmacy, By Value (USD Million), 2017-2027
5.3.2 Retail Pharmacy - Market Size and Forecast (2017-2027)
Table 15: Global Alzheimer's Drugs Market- By Retail Pharmacy, By Value (USD Million), 2017-2027
5.3.3 Online Pharmacy - Market Size and Forecast (2017-2027)
Table 16: Global Alzheimer's Drugs Market- By Online Pharmacy, By Value (USD Million), 2017-2027
6. Global Alzheimer's Drugs Market: Regional Analysis
6.1 Competitive Scenario of Global Alzheimer's Drugs Market : By Region
Table 17: Global Alzheimer's Drugs Market- By Region Market Share, 2021 & 2027
7. North America Alzheimer's Drugs Market: An Analysis (2017-2027)
7.1 North America Alzheimer's Drugs Market : Size and Forecast (2017-2027), By Value
Table 18: North America Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 19: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 20: North America Population ages 65 and above (% of total Population), 2016-2020
Table 21: United States lifetime risk for Alzheimer's's dementia at age 45 and 65 for both Men and Women, 2020 (In %age)
7.2 North America Alzheimer's Drugs Market - Prominent Companies
7.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and Others)
Table 22: North America Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
7.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
Table 23: North America Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
7.5 North America Alzheimer's Drugs Market: Country Analysis
7.6 Market Opportunity Chart of North America Alzheimer's Drugs Market - By Country, By Value, 2027
Table 24: Market Opportunity Chart of North America Alzheimer's Drugs Market- By Country, By Value (Year 2017-2027)
7.7 Competitive Scenario of North America Alzheimer's Drugs Market: By Country
Table 25: North America Alzheimer's Drugs Market- By Country Market Share, 2021 & 2027
7.8 United States Alzheimer's Drugs Market: Size and Forecast (2017-2027), By Value
Table 26: United States Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 27: United State Number of People Living with Alzheimer'sís Disease, By Age (In Millions), 2020
Table 28: Alzheimer's's disease mortality rate in the United States from 2015 to 2019, (per 100,000 population)
Table 29: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 30: United States Percentage Changes in Selected Causes of Death (All Ages) Between 2000 and 2019, (In %age)
Table 31: United State Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 32: United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 33: United States Population aged 65 and above (% of total Population), 2016-2020
7.9 United States Alzheimer's Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
Table 34: United State Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Table 35: United State Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
7.10 Canada Alzheimer's Drugs Market: Size and Forecast (2017-2027), By Value
Table 37: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 38: Canada Death Rate for Alzheimer's Disease (Per 100,000 Population), 2015-2019
Table 39: Canada Population aged 65 and above (% of total Population), 2016-2020
7.11 Canada Alzheimer's Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
Table 40: Canada Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Table 41: Canada Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
8. Europe Alzheimer's Drugs Market: An Analysis (2017-2027)
8.1 Europe Alzheimer's Drugs Market : Size and Forecast (2017-2027), By Value
Table 42: Europe Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 43: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 44: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 45: European Countries Population ages 65 and above (% of total Population), 2020
8.2 Europe Alzheimer's Drugs Market - Prominent Companies
8.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and Others)
Table 46: Europe Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
8.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
Table 47: Europe Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
8.5 Europe Alzheimer's Drugs Market: Country Analysis
8.6 Market Opportunity Chart of Europe Alzheimer's Drugs Market - By Country, By Value, 2026
Table 48: Market Opportunity Chart of Europe Alzheimer's Drugs Market- By Country, By Value (Year 2017-2027)
8.7 Competitive Scenario of Europe Alzheimer's Drugs Market: By Country
Table 49: Europe Alzheimer's Drugs Market- By Country Market Share, 2021 & 2027
8.8 Germany Alzheimer's Drugs Market: Size and Forecast (2017-2027), By Value
Table 50: Germany Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 51: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 52: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 53: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
8.9 Germany Alzheimer's Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
Table 54: Germany Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Table 55: Germany Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
8.10 United Kingdom Alzheimer's Drugs Market: Size and Forecast (2017-2027), By Value
Table 56: United Kingdom Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 57: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 58: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 59: United Kingdom Population ages 65 and above (% of total Population), 2016-20
8.11 United Kingdom Alzheimer's Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
Table 60: United Kingdom Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Table 61: United Kingdom Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
8.12 France Alzheimer's Drugs Market: Size and Forecast (2017-2027), By Value
Table 62: France Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 63: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 64: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 65: France Population ages 65 and above (% of total Population), 2016-20
8.13 France Alzheimer's Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
Table 66: France Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Table 67: France Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
8.14 Italy Alzheimer's Drugs Market: Size and Forecast (2017-2027), By Value
Table 68: Italy Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 69: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 70: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 71: Italy Population ages 65 and above (% of total Population), 2016-20
8.15 Italy Alzheimer's Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
Table 72: Italy Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Table 73: Italy Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
9. Asia Pacific Alzheimer's Drugs Market: An Analysis (2017-2027)
9.1 Asia Pacific Alzheimer's Drugs Market : Size and Forecast (2017-2027), By Value
Table 74: Asia Pacific Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 75: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 76: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 77: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
9.2 Asia Pacific Alzheimer's Drugs Market - Prominent Companies
9.3 Market Segmentation By Drug Class (Cholinergic, Memantine, Combined drug and Others)
Table 78: Asia Pacific Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
9.4 Market Segmentation By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)
Table 79: Asia Pacific Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
9.5 Asia Pacific Alzheimer's Drugs Market: Country Analysis
9.6 Market Opportunity Chart Asia Pacific Alzheimer's Drugs Market - By Country, By Value, 2027
Table 80: Market Opportunity Chart of APAC Alzheimer's Drugs Market- By Country, By Value (Year-2027)
9.7 Competitive Scenario of Asia Pacific Alzheimer's Drugs Market: By Country
Table 81: APAC Alzheimer's Drugs Market- By Country Market Share, 2021 & 2027
9.8 China Alzheimer's Drugs Market: Size and Forecast (2017-2027), By Value
Table 82: China Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 83: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 84: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 85: China Population ages 65 and above (% of total Population), 2016-20
9.9 China Alzheimer's Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
9.10 Japan Alzheimer's Drugs Market: Size and Forecast (2017-2027), By Value
Table 88: Japan Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 89: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 90: Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 91: Japan Alzheimer'sís Drugs company market share (%), 2020
Table 92: Japan Population ages 65 and above (% of total Population), 2016-20
9.11 Japan Alzheimer's Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
Table 93: Japan Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Table 94: Japan Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
9.12 India Alzheimer's Drugs Market: Size and Forecast (2017-2027), By Value
Table 95: India Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 96: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Table 97: e-pharmacy market in India (USD million)
Table 98: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 99: India Population ages 65 and above (% of total Population), 2016-20
9.13 India Alzheimer's Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
Table 100: India Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Table 101: India Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
9.14 Australia Alzheimer's Drugs Market: Size and Forecast (2017-2027), By Value
Table 102: Australia Alzheimer's Drugs Market Size, By Value, 2017-2027 (USD Million)
Table 103: Australia current health expenditure (% of GDP), (2014-2018)
Table 104: Australia population aged 65 and above (% of total population), 2017-2021
Table 105: Australia urban population (% of total population), 2017-2021
9.15 Australia Alzheimer's Drugs Market Segmentation - By Drug Class, By Distribution Channel (2017-2027)
Table 106: Australia Alzheimer's Drugs Market - By Drug Class, By Value (USD Million), 2017-2027
Table 107: Australia Alzheimer's Drugs Market - By Distribution Channel, By Value (USD Million), 2017-2027
10. Global Alzheimer's Drugs Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Alzheimer's Drugs Market - By Drug Class, 2027
11.2 Market Attractiveness Chart of Global Alzheimer's Drugs Market - By Distribution Channel, 2027
Table 109: Market Attractiveness Chart of Global Alzheimer's Drugs Market- By Distribution Channel (Year 2017-2027)
11.3 Market Attractiveness Chart of Global Alzheimer's Drugs Market - By Region, 2027
Table 110: Market Attractiveness Chart of Global Alzheimer's Drugs Market- By Region (Year 2017-2027)
12. Competitive Landscape
12.1 Product Pipeline of Leading Alzheimer's Drugs Companies
12.2 Market Share Analysis
Table 111: Global Alzheimer'sís Drugs company market share (%), 2020
13. Company Analysis
13.1 AbbVie Inc.
Table 112: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
Table 113: AbbVie Inc. Net Income (USD Million), 2016-2020
Table 114: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
Table 115: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
13.2 F. Hoffman-La Roche, Ltd.
Table 116: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Table 117: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Table 118: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Table 119: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
13.3 Novartis AG
Table 120: Novartis Annual Sales Revenue (USD Million), 2016-2020
Table 121: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Table 122: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Table 123: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
13.4 Biogen
Table 124: Biogen Sales Revenues, 2016-2020 (USD Million)
Table 125: Biogen Net Profit, 2016-2020 (USD Million)
Table 126: Biogen, By Business Segment (%), FY2020
Table 127: Biogen, By Geographical Segment (%), FY2020
13.5 Pfizer Inc.
Table 128: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
Table 129: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
Table 130: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
13.6 Eli Lilli and Company
Table 131: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Table 132: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
Table 133: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Table 134: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
13.7 Takeda Pharmaceutical Company Limited
Table 135: Takeda Pharmaceutical Company Limited Sales Revenues, 2016-2020 (USD Million)
Table 136: Takeda Pharmaceutical Company Limited Net Income, 2016-2020 (USD Million)
Table 137: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Business Segment (%), FY2020
Table 138: Takeda Pharmaceutical Company Limited Sales Revenue Split, By Geography Segment (%), FY2020
13.8 Novo Nordisk
Table 139: Novo Nordisk Sales Revenues, 2016-2020 (USD Million)
Table 140: Novo Nordisk Net Profit, 2016-2020 (USD Million)
Table 141: Novo Nordisk Sales Revenue Split, By Business Segment (%), FY2020
Table 142: Novo Nordisk Sales Revenue Split, By Geography Segment (%), FY2020
13.9 Daiichi Sankyo Company Ltd.
Table 143: Daiichi Sankyo Company Ltd. Revenue, 2020-2021 (In USD Million)
Table 144: Daiichi Sankyo Company Ltd. Sales Revenue Split, By Business Segment (%), FY2020
Table 145: Daiichi Sankyo Company Ltd. Sales Revenue Split, By Geography Segment (%), FY2020
Table 146: Eisai Co. Ltd. Revenue, 2019-2020 (In USD Billion)
13.10 Eisai Co. Ltd
Table 146: Eisai Co. Ltd. Revenue, 2019-2020 (In USD Billion)
Table 147: Eisai Co. Ltd. Revenue by Reporting Segment, FY2020
13.11 NervGen Pharma

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings